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7COMMENTSI

South Africa's Medicines and Related
Substances Control Amendment Act: A
Spoonful of Sugar or a Bitter Pill to
Swallow?I.

Introduction

As the lead advocate for the new law, South Africa's Minister
of Health, Nkosasana Zuma, faced opposition from the multinational pharmaceutical industry giants and the world's most
powerful nations, and yet, for now at least, she has won. South
Africa passed the Medicines and Related Substances Control
Amendment Act (hereinafter the "Act") in December of 1997 in an
effort to lower the cost of medicines and thereby improve access to
medical care for many impoverished South Africans.'
While primary healthcare has been entitled by law to all citizens
of South Africa since 1996, most South Africans are still unable to
receive even the most basic medical care. Today, less than one-fifth
This comment is dedicated to my wife Jennifer for it was not the work of
one intellect and conscience, but of two, which made it a reality.
1. See Medicines and Related Substances Control Amendment Bill (visited Oct.
14, 1998) <http://www.anc.org.za/as/ pubs/whip /whip22.html>.
2. See Nigel Benetton, Changes to the Law Promise Less Flexibility for Medical
Schemes (visited Oct. 14, 1998) <http: //www.woza.za.com.>. Primary health care
includes "basic emerg-ency first aid treatment, immuni[z]ation, education, especially
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of the population "is consuming over half of the healthcare
resources." Many rural clinics still do not have running water or
electricity,
• • 4 and even fewer clinics are assured a steady supply of

medicines. To further complicate matters, South Africa currently
endures over 20,000 cases of malaria and 160,000 cases of
tuberculosis each year.5 Unfortunately, however, there is an even

bigger problem facing South Africa: AIDS. South Africa has one of
the highest growth rates of HIV in the world, with 2.4 million people
infected which represents 6.3 percent of the population.6 Thus, it is
no wonder that Minister of Health Zuma considers the new law to
be a desperately needed step in beginning to heal the nation's ailing
health care system.7

Critics, however, are quick to point out that the new law is far
from being
a panacea for the problems currently affecting the
8
nation. Many see the new law as an impending disaster. 9 The Act
has been surrounded by controversy because it seeks to lower

pharmaceutical prices by changing existing patent laws.' °

The

United States Trade Representatives' 1998 annual report identified

the new law as "[the United States'] largest patent rights concern.""
Accordingly,

United

States

Trade

Representative

Charlene

Barshefsky announced the placement of South Africa on the Watch
List for countries
who provide inadequate intellectual property right
2

protection.'

with [regard to] sexually transmitted diseases, disease control and the provision of
clean running water, for example." Id.
3. See id.
4. See id.
5. See id.
6. See Benetton, supra note 2. And as the demand for medicines has
increased, so have prices. Figures from the Representative Association of Medical
Schemes show that the price of medicines rose 37 percent in 1990, rose 45 percent
the subsequent year, and the increased another 14 percent in 1994. Pat Sidley,
Vested Interests Resist Reform in Medicines, BUSINESS TIMES, visited Oct. 15, 1998,
<http://www.btimes.co.za/97/0504/news/newsl7.htm>.
7. See Benetton, supra note 2.
8. See Donald G. McNeil, Jr., South Africa's Bitter Pill for World's Drug
Makers, N.Y. TIMES, Mar. 29, 1998, at Section 3, Page 1.
9. See id.
10. See id.
11. Simon Barber, US Court Decision Holds No Sway Over Battle With SA,
Bus. DAY, Mar. 18, 1998, at 13.
12. USTR Announces Results of Special 301 Annual Review, USTR PRESS
RELEASE, May 1, 1998, at 6, 21. Under the Special 301 provisions of the Trade Act
of 1974, the USTR has the authority to place higher duties and restrictions on
imports from countries that provide inadequate intellectual property protection. See
also Stefan Kirchanski, Protection of U.S. Patent Rights in Developing Countries:
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The new law has also sparked responses from private industry. 3
One major United States drug manufacturer threatened that if the
law were not changed it would halt all operations in South Africa,
thereby eliminating thousands of jobs. 14 The pharmaceutical
companies claim that in order to lower prices, changes could be
made in South Africa's inefficient distribution chain by eliminating
extensive price mark-ups by middlemen and by stopping the theft of
drugs from public hospitals.
Furthermore, the International
Federation of Pharmaceutical Manufacturers indicated that
companies may retaliate against South Africa by refusing to
introduce new drugs, including any new Aids medications, unless the
law is changed. 6 Thus, the question remains whether the new law
will help ameliorate the condition of many South African people or
whether they will end up suffering even greater harms.
This comment examines the potential benefits and problems
presented by the Medicines and Related Substances Amendment
Act as it relates to pharmaceutical patent rights in South Africa.
Part II provides a background on some basic principles of
intellectual property law that are relevant to the new law. Part III
then looks at the changes made to the laws of South Africa with the
passage of the Act. Part IV examines the effect of the Act on South
Africa's compliance with the Trade Related Aspects of Intellectual
Property Rights Agreement ("TRIPS"). Part V discusses the pros
and cons of the new law. Part VI then summarizes and concludes
that the new law may be beneficial to South Africa.
II.

Intellectual Property Law Fundamentals

A. Intellectual Property
Intellectual property is "intangible property that is a product of
human creativity, such as books, films or inventions.', 17 Intellectual
property laws attempt to provide the protections that normally
accompany ownership of tangible property to the "intangible
U.S. Efforts to Enhance PharmaceuticalPatents in Thailand, 16 Loy. L.A. INT'L &

COMP. L.J. 569, 588 (1994). However, South Africa was only placed on the Watch
List of less severe offenders, which means they will be subject to "out-of-cycle
reviews," but not be subject to trade sanctions. Id.
13.

See Mary Braid, Drug Giants Flex Muscles as SA Tries to Cut Health Bill,

INDEPENDENT

(London), Oct. 8, 1997, at 14.

14.
15.

See id.
See id.

16.
17.

See id.
See Kirchanski, supra note 12, at 570.
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products of mental labor."'" The primary protection the law seeks to
secure for intellectual property is exclusivity. As patent attorney
Peter D. Rosenberg explained, "the essence of property is the
exclusive right to enjoy it."' 9 While intellectual property undoubtedly has economic value, as it may be bought, sold and otherwise
exploited commercially, the product of mental labor has not always
been provided legal protection. 2° Indeed, some countries still rely on
the free-market, through self-protection, to provide adequate
21
protection for intellectual property.
B.

The Benefits and Costs of Intellectual PropertyLaws

Under a free-market approach, the inventor, author or other
creator of intellectual property would still retain the right to make,
22
use or sell his or her invention. However, in the absence of legal
protection, there is nothing to prevent someone from copying the
invention and using it.23 Consequently, someone who copies and
sells the invention is competing with the original inventor, and
therefore, the inventor's ability to sell and profit from his or her own
24
invention is diminished. The copier also has the advantage of being
able to compete without bearing the investment, time or effort
necessary for the discovery, and as a result, the copier might make
25
more money from the invention than the inventor. Most countries,
however, believe the unfettered use of another person's inventions is
unjust. And as a result, countries have enacted intellectual property
laws to provide the inventor the sole benefit of his or her invention
26
by excluding others from enjoying the invention.
In other words,
the government grants the inventor a monopoly on the sale of his or
her invention.27
Not only do advocates of intellectual property believe the grant
of a monopoly to inventors is fair, but they also believe it improves

the "size, quality, and efficiency of both the labor force and the

18. See id.
19. PETER D. ROSENBERG, PATENT LAW FUNDAMENTALS, at 1-7 (2d ed. 1980).
20. See Kirchanski, supra note 12, at 570.
21. See Theresa Beeby Lewis, PatentProtectionfor the PharmaceuticalIndustry:
A Survey of the Patent Laws of Various Countries,30 INT'L L. 835, 837 (1996).
22. See ROSENBERG, supra note 19, at 1-5.
23. See id. at 1-5, 1-6.
24. See id. at 1-6.
25. See id.
26. See id. at 1-4.
27. See ROSENBERG, supra note 19, at 1-6.
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capital stock within a country., 2' They believe that the reduction in
competition, due to the grant of the monopoly, increases the
profitability of inventions and therefore encourages the search for
and, as a result, the discovery of new inventions.29 Ultimately,
advocates of intellectual property rights believe that the increased
number of inventions benefits the economy as well as society's well
being. 3° But there is a cost associated with granting an inventor a
monopoly.31 Inventors may charge premium prices, commonly
referred to as royalties, for their inventions." Thus, countries that
have adopted intellectual property laws have presumably concluded
that the cost to society from the royalties due to the monopoly are
outweighed by the benefits of the new inventions.33
C. Patent Law

In its most plain sense, a patent is simply a contract entered into
by an inventor and a government.34 The government promises to
provide the inventor a monopoly to the enjoyment, of his or her
invention in return for disclosure of the invention to the public.35
Indeed, the word "patent" is commonly understood to mean open or
obvious."

The justification for disclosure is that it will "catalyze other
37
inventors activity and make possible additional advances in the art
by allowing them "to think and to write about what is covered by the
patent." 38 Otherwise, a discovery could potentially be kept a secret
forever.39 The life of a patent, however, is usually limited to a certain
amount of time, such as 20 years in the United States. 4°

28. See Lewis, supra note 21, at 838.
29. See Kirchanski, supra note 12, at 572.
30. See id.
31. See id. One author noted that there is a significant difference between a
government granted monopoly in a patent and other monopolies. Rosenberg, supra
note 19, at 1-7. He noted that "[u]nlike a franchise, a patent deprives the public of
nothing that it freely enjoyed prior to the grant of the patent." See id. Nonetheless,
prospective costs remain.
32. See Kirchanski, supra note 12, at 572.
33. See id.
34. See ROSENBERG, supra note 19, at 1-4.
35. See id.
36. See id. at 1-1.
37. See id. at 1-4.
38. See id. at 1-8.
39. See ROSENBERG, supra note 19, at 1-4.
40. See Lewis, supra note 21, at 837.
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Consequently, the public may use and enjoy the invention after the
patent has expired.
Normally, when "an invention is novel, useful, and not obvious,
it is patentable if it falls within the patentable categories provided in
a particular country., 42 Countries vary as to which inventions are
patentable. 43 There is often international controversy in patent law
because some developing countries do not allow patents for certain
categories of inventions, such as new medicines or agricultural
inventions." Countries refuse to allow patents in these categories
because, among other reasons, they believe the cost to their
economy would be too great or the prices of important discoveries
would be prohibitive for their citizens. 4' The international
controversy concerning the existence of a patentable category for
pharmaceuticals in South Africa is the matter addressed by this
comment.
D. ParallelImports
This comment also deals with the allowance of parallel imports
in South Africa. Parallel imports are "goods which are bought in a
foreign market by an independent third party, and then resold in
[another] market to compete with authorized distributors., 46 Despite
many efforts to harmonize and increase intellectual property
protection around the world, there still exists a significant number of
countries that permit parallel imports.47 As a result, companies that
sell their products abroad may experience increased competition
from their own goods.4a Even multinational companies that only
produce goods in countries that do not permit parallel imports, such
as the United States, still run the risk of unauthorized dealers buying
goods and selling them in other countries in competition with
authorized foreign dealers.49
The impetus for diverting foreign bound goods from one
country to another is usually the potential to profit from different

41. See id.
42. See id.
43. See id.
44. See id. at 837.
45. See Lewis, supra note 21, at 835.
46. Hillary A. Kremen, Caveat Venditor: InternationalApplication of the First
Sale Doctrine, 23 SYRACUSE J. INT'L L. & COM. 161 (1997).
47. See id.
48. See id.
49. See id.
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prices. ° Companies often discriminate in pricing between countries
for a couple of reasons.5 First, authorized distributors may pay to
promote and advertise the patented product in some countries
where other, authorized dealers do not." Second, authorized dealers
often provide product support and service for their goods. 3
Unauthorized dealers also exploit currency fluctuations, buying in
one country when its currency is weak and selling in another where
the currency is stronger. 4
Parallel imports, through increased competition, have obvious
Increased competition will
potential benefits for consumers.5
pressure companies to lower the price of their product Indeed, the
price discrimination must be substantial, with prices drastically
higher in one country, for the unauthorized dealers to be able to
offer a lower price on goods which must be transported between
countries. 7 In short, the controversy surrounding parallel imports
centers on whether or not patent protection should extend beyond
the first sale of a product. 8
E. FirstSale Doctrine
The "first sale" doctrine if applied internationally would permit
parallel imports because it limits patent protection to the first
disposition of goods.5 9 Under this doctrine, a patentee loses the
ability to control, and the royalties from, subsequent dispositions of
the patented goods. 6° The patent is said to have been "exhausted"
upon the first sale of the good. 6' Thus, the purchaser of a patented
good is free to resell the good without violating any patent laws and
61
giving rise to a cause of action on behalf of the patentee.

50. See id. at 162.
51. See Kremen, supra note 46, at 162.
52. See id.
53. See id.
54. See id.
55. See James Love, Comments of the Consumer Project on Technology to the
Portfolio Committee on Health Parliament (visited Oct. 14, 1998) <http://www
.cptech.or/pharm/sasa-10-97.html>.
56. See id.
57. See id.
5& See Kremen, supra note 46, at 162, 163.
59. See id. at 162.
60. See id.
61. See id.
62. See id.
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The first sale doctrine is normally applied only to subsequent
sales of patented goods that occur domestically." Countries have
been hesitant to apply the first sale doctrine internationally due to
the fear that importers would re-direct goods from poorer countries
to the countries where the price is higher, and as a result,
economically disadvantaged countries would be denied sufficient64
supplies of goods and technology that are extremely beneficial.
Ultimately, allowing parallel imports limits the monopoly power
granted to patent holders, and therefore, the first sale doctrine
reduces the level of intellectual property protection provided to
65
multinational companies.
III. The Medicines and Related Substances Control Amendment
Act's Effect on the Laws of South Africa.
A.

The Ministerof Health's Powers Under Section 15(C)(a).

South Africa has increased intellectual property rights
protection in recent years. After the Uruguay Round trade
negotiations of the General Agreement on Tariffs and Trade
("GATT") over Trade Related Aspects of Intellectual Property
Rights agreement ("TRIPS"), South Africa, along with the other
6
GATT members, signed the TRIPS agreement on April 15, 1994.
And in 1997, South Africa made buying and selling of counterfeit
goods a crime. 67 Indeed, the Patents Act of 1978 provided patent
protection for medicines, and Subsection 1(2) outlawed parallel
imports.6 8

Despite the trend toward increasing intellectual property
protection, many people believe the new law empowers the Minister
69
of Health to selectively end patent rights for pharmaceuticals.
Under Section 15(C)(a),

63. See Kremen, supra note 46, at 162.
64. See id. at 162, 163.
65. See id. at 163.
66. See Tony Hooper, Peter Davies, The Medicines and Related Substances
Control Amendment Bill (B30-97) and Its Effect on Intellectual Property Rights
(visited on Oct. 14, 1998) <http://www.spoor.co.za/lib/genericdrugs.html>.
67. See USTR, supra note 12, at 21,22.
68. See Hooper, supra note 66.
69. See McNeil, supra note 8. See also, Simon Barber, Plan Blunts Long-Term
Threat to US Aid for SA, Bus. DAY (S. Afr.), July 20, 1998, at 3. (Stating that the
new law "appears to give the SA health minister the power to abrogate drug patents
for the sake of controlling medicine costs." Id.)
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[the Minister of Health] so as to protect the health of the
public may... notwithstanding anything to the contrary
contained in the Patents Act, 1978 (Act No. 57 of 1978),
determine that the rights with regard to any medicine under a
patent granted in the Republic shall not extend to acts in
respect of such medicine which has been put onto the market
70
by the owner of the medicine, or with his or her consent.
The United States Congress and some European countries have
stated that they interpret this section to allow the Minister of Health
to approve the use of more affordable medicines in violation of any
patent right under the 1978 Patents Act of South Africa.7 1 Minister
of Health Zuma steadfastly denies that the provision ends patent
rights.72 Instead, she claims that the provision is only aimed at
permitting parallel imports of medicines." While the Act does
permit parallel imports under section 15(C)(b), as will be discussed
subsequently, it remains unclear whether or not section 15(C), as a

70. Medicines and Related Substances Control Amendment Act, No. 101
(1997) (S. Afr.). The entirety of section 15C reads as follows:
Measures to ensure supply of more affordable medicines 15C.
The Minister may prescribe conditions for the supply of more
affordable medicines in certain circumstances so as to protect
the health of the public, and in particular may
(a) notwithstanding anything to the contrary
contained in the Patents Act, 1978 (Act No. 57 of
1978), determine that the rights with regard to any
medicine under a patent granted in the Republic shall
not extend to acts in respect of such medicine which
has been put onto the market by the owner of the
medicine, or with his or her consent;
(b) prescribe the conditions on which any medicine
which is identicalin composition, meets the same
quality standard and is intended to have the same
proprietary name as that of another medicine already
registered in the Republic, but which is imported by a
person other than the person who is the holder of the
registration certificate of the medicine already
registered and which originates from any site of
manufacture of the original manufacturer
as
approved by the council in the prescribed
manner,
may be imported;
(c) prescribe the registration procedure for, as well
as the use of, the medicine referred to in paragraph
(b).
71. See McNeil, supra note 8.
72- See id.
73. See id. For an explanation of parallel imports and their potential effect on
patent rights in South Africa see discussion supra Parts II.D. and infra Parts III.B.
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whole, seeks to infringe on patent rights more so than the
approbation of parallel imports.
In defending the new law, South African Trade and Industry
Minister Alec Erwin stated that "the government had taken a policy
decision to stop drug companies from using their patents to prevent
affordable health care."75 While this is surely the case, the extent to
which the law infringes on patent rights .is unclear. Upon closer
examination, the law does not appear to give the Minister of Health
the absolute power to abrogate patent rights, but instead the law
seems to simply give her the power to authorize parallel imports."
The part of section 15(C)(a) that has caused confusion is the
language stating that pharmaceutical patent rights "shall not extend
to acts in respect of such medicine which has been put onto the
market."77 While it is unclear what "acts" are excluded from patent
protection, it is clear that the law only addresses medicine which has
been "put onto the market" by the owner. If the phrase "put onto
the market" means broadly those patented medicines that have been
exploited commercially, the law could deny patent holders any
benefits of patent protection once they begin to sell their drugs. This
would mean that once a pharmaceutical company proceeds to sell
their patented medicine they have put their patented drugs "onto
the market," and the Minister of Health then may authorize the
production of a drug that is an exact copy of the patented product.
If this interpretation is correct, the new law would allow the
Minister of Health to effectively choose to abrogate patent rights
whenever she deems it to be in the best interest of the public's
health.7' However, this does not appear to be the best interpretation of this section. The major importance of a patent is the
right to exploit it commercially, and under this interpretation, a
pharmaceutical patent would be essentially useless without the
approval of the Minister of Health. It seems very unlikely that the
legislature of South Africa would choose to entrust a single
government official with the power to upend an entire area of
established law without a much clearer declaration than 15(C)(a).
Dr. Zuma, who has been the lead advocate of the new law and
would be vested with this broad new power as Minister of Health,
74. See USTR, supra note 12, at 21.
75. See Jacob Dlamini, Erwin Defends Drugs Law, Suggests WTO Intervention,
Bus. DAY (S. Aft.), Oct. 22, 1997, at 2.
76. See supra note 15 for the entire text of Section 15C of the new law.
77. Medicines and Related Substances Control Amendment Act, No. 101
(1997) (S. Afr.) § 15C(a).
78. See McNeil, supra note 8.
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has stated clearly that she does not believe the new law gives her the
power to end all pharmaceutical patent rights. 9 It appears she is
correct.
The phrase "put onto the market" most likely refers to each
individual parcel of medicine that has been sold. Thus, a person
loses patent protection against the resale of his or her goods. This is
commonly known as the first sale doctrine and would effectively
empower the health minister to allow people to parallel import a
manufacturer's patented pharmaceuticals sold in other countries
into South Africa. This would mean that a patent holder would still
receive all of the -benefits of the patent before and including the
original sale of the medicine, but would lose protection against
subsequent reselling by a buyer. While allowing parallel imports is a
reduction in the patent protection afforded to pharmaceuticals, this
interpretation seems much more reasonable than a near complete
termination of pharmaceutical patent rights, especially in light of
section 15(C)(b)'s express acceptance of parallel imports.'s
At the very least, the language in 15(C)(a) needs to be clarified
during the promulgation of regulations. If the complete, albeit
selective, dissolution of patent protection for pharmaceuticals is in
fact not the intent of this the new law, then it should be made clear
that pharmaceutical patents will be honored in order to eliminate
any confusion. As it stands, the new law appears to simply empower
the Minister of Health to allow parallel imports. But the possibility
that the Minister of Health may exploit the language of 15(C)(a) to
further reduce patent protection can only increase the risk of
investment from pharmaceutical companies. For the purposes of
this comment, the new law will be analyzed under the assumption
that section 15(C)(a) gives the Minister of Health broad powers to
abrogate pharmaceutical patents, and subsequently, as if the new
law only provides for parallel imports, as is evident in section
15(C)(b) discussed below.

79. See id.
80. Section 15(C)(a) also states that the Minister of Health may act to protect
the public health "notwithstanding anything to the contrary contained in" the
Patents Act of 1978. § 15(C)(a). While this language clearly limits the application of
the Patents Act, if all section 15(C), as a whole, does is permit parallel imports, then
the only part of the Patents Act which is repealed is its prior prohibition of parallel
imports under section 1(2) of the 1978 Patents Act.
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The New Law's Approval of ParallelImports Under Section
15(C) (b).

Unlike 15(C)(a) of the Act, the language of section 15(C)(b)
has a much clearer intent. Section 15(C)(b) of the new law explicitly
reverses the 1978 Patents Act's prohibition on parallel imports.
More specifically, the new law states that a drug that "meets the
same quality standards and is intended to have the same proprietary
name as that of another medicine already registered in the Republic,
but which is imported by a person other than the person who is the
holder of the registration certificate ... may be imported."82 Under

this section, "a medicine which is available abroad and which is
identical to one registered by the same manufacturer in South Africa
need not be the subject of a separate registration and may therefore
be imported and sold in competition with the product which is the
subject of the local registration., 83 This provision is aimed at
increasing local price competition and lowering prices by allowing
the importation of drugs from other countries where they are
cheaper.' 4 It has also been suggested that this section gives South
Africa, and in particular Minister of Health Zuma, leverage to force
the industry to lower their prices.85 Dr. Zuma can threaten to begin
parallel importation of a manufacturer's drugs from other countries
if the local prices do not conform with rates abroad. 6
IV. Compliance of the Act with South Africa's International
Obligations Under TRIPS.
Negotiations during the Uruguay Round of the GATT resulted
in South Africa signing TRIPS in 1994. 87 Article 7 of the TRIPS
accord states that the objective of the TRIPS agreement is:
[t]he protection and enforcement of intellectual property rights
should contribute to the promotion of technological innovation
and to the transfer and dissemination of technology, to the

81. See id. at § 15(C)(b).
82. See id. at § 15(C)(b). See supranote 14 for entire section.
83. See Hooper, supra note 66.
84. See Love, supra note 55. For a discussion of parallel imports and their
potential effect on patent rights in South Africa and South Africa's compliance with
the TRIPS agreement see supra p. 11, 12 and see infra p. 12-14.
85. See Dlamini, supra note 75.
86. See id.
87. See Suresh Koshy, The Effect of TRIPS on Indian Patent Law: A
PharmaceuticalIndustry Perspective, 1 B.U. J. SCI. & TECH. L. 4 (1995).
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mutual advantage of producers and users of technological
knowledge and in a manner conducive to social and economic
welfare, and to a balance of rights and obligations."
While the TRIPS agreement sought to harmonize intellectual
property law between countries, members may implement local laws
that provide more patent protection than the minimum protections
mandated in TRIPS.89 However, the Medicines and Related
Substances Amendment Act may provide less protection than South
Africa is permitted under TRIPS.
A.

TRIPS Does Not Authorize South Africa or Any Other
Member Country to Exclude PharmaceuticalsFrom Product
Patent Protection.

Article 28(1) requires member countries to provide patent
protection for the exclusive rights of "making, using, offering for
sale, - selling, or importing" a product or process. 9° A patentable
product or process can be any invention "in all fields of technology,
provided they are new, involve an inventive step and are capable of
industrial application."' 91 However, "[m]embers may exclude from
patentability inventions... within their territory of the commercial
exploitation which is necessary to protect.., public [morals,] ...
human, animal or plant life or health or to avoid serious prejudice to
the environment., 92 Furthermore, Article 27(3) allows member
countries to "exclude from patentability: (a) diagnostic, therapeutic
and surgical methods for the treatment of humans or animals." 93

But there is no exception for pharmaceuticals. As a result, it would
appear that Section 15(C)(a) of the Medicines and Related
Substances Control Amendment Act would violate the TRIPS
agreement if, as some critics claim, it gives the Health Minister
broad powers to eliminate such patents. 94

88. Agreement On Trade-Related Aspects of Intellectual Property Rights,
Including Trade in Counterfeit Goods, Final act Embodying The Results of The
Uruguay Round of Multilateral Trade Negotiations, 33 I.L.M. 83, 86-87 (1994).
[hereinafter TRIPS].
89. See Koshy, supra note 87.
90. TRIPS, supra note 88, at 94. However, "[t]his right, like all other rights
conferred under this Agreement in respect of the use, sale, importation or other
distribution of goods, is subject to the provisions of Article 6.A Id.
91. See id. at 93.
92. See id. at 94.
93. See id.
94. See McNeil, supra note 8.
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B.

Article 6 of TRIPS Does Not ProhibitSouth Africa From
PermittingParallelImports.

It does not appear that parallel imports are a violation of the
GATT's TRIPS accords. Some pharmaceutical manufacturers have
argued that TRIPS prohibits parallel imports.95 They point to the
fact that TRIPS Article 28 "gives the patent owner the exclusive
rights to import [their] good." '96 However, the right to import is
limited by Article 6 of TRIPS. 9 Article 6 makes it clear that
"nothing in this Agreement shall be used to address the issue of
exhaustion of intellectual property rights." 98

The theory behind the doctrine of exhaustion, or first sale
doctrine, is that the owner of the property right has benefitted from
the protection upon the products first sale.9 Subsequently, a buyer
may resell the product in competition with the patent holder without
infringing on his or her patent rights.' ° This presents an opportunity
for importers to acquire patented, products, including medicines,
from other countries where the price is lower and then import the
product into a market where the price is higher.'0 ' Thus, under the
doctrine of exhaustion, parallel imports do not violate patent rights.
TRIPS was the first intellectual property treaty to directly
address parallel imports.)° But all it decided was that such disputes
are to be settled between individual countries.) ° Thus, there is no
impediment in international law to parallel imports, and it does not
appear that the Medicines and Related Substances Amendment Act
has violated South Africa's obligations under TRIPS.
V.

The Potential Benefits and Problems of the New Law.

A.

The Minister of Health's PotentialPower Under Section
15(C)(a) to Abrogate PatentProtectionsfor Pharmaceuticals.

The traditional rationale for the existence of a patent system is
that society benefits from more innovations and that the best way to

95.
96.
97.
9&
99.
100.
101.
102.
103.

See Love, supranote 55.
See id.
See id.
See id.
See id.
See Love, supra note 55.
See Kremen, supra note 46, at 162.
See id. at 173, 174.
See id. at 174.
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cultivate them is through patent exclusivity' °4 Some potential
benefits of a South African pharmaceutical patent system include:
(1) greater foreign and domestic investment for research and
development; (2) greater "transfer of pharmaceutical technology" to
South Africa; and (3) greater availability of drugs. °5 For a
developing country, however, these benefits may prove somewhat
illusory, and ultimately, the costs of the patent system may outweigh
the benefits.
It has been argued "that the policies justifying the protection of
patents in developed countries are not necessarily applicable to
developing countries."'O In some cases, piracy can benefit a country
by simply providing patented technology without the additional cost
of having to pay a royalty to acquire it.'0 The country's economy not
only receives a windfall from this cost savings, but also from
exporting the counterfeit goods to other countries that also lack
patent protections.'O' Similarly, the availability or supply of new
drugs, which are often extremely expensive, might be limited by the
low income of most South Africans.' °9 Furthermore, as a developing
country, the potential benefit of increased investment in local
research and development and manufacturing facilities may be
unlikely because of a lack of "trained technicians and other
infrastructure" in South Africa."°
While these arguments undoubtedly have merit, they do not
seem to ring true for South Africa. First, there appears to be
adequate infrastructure to support domestic research and
development and manufacturing facilities."' The 12 American
pharmaceutical companies with facilities in South Africa together
take in nearly 100 billion pounds in revenue a year."' Indeed, they
account for less than half of the $2 billion-a-year drug market in
South Africa."3 Thus, it appears that South Africa does have the

104.

See id. A. Samuel Oddi, The International Patent System and Third World

Development, Reality or Myth?, 1987 DuKE L.J. 831, 837 (1987). For a discussion of
the rationale behind intellectual property rights or patents see discussion supra Parts
II.B.
105. See Kirchanski, supra note 12, at 577.
106. See id. at 570.
107. See id. at 577.
108.

See id.

109.
110.
111.
112.
113.

See
See
See
See
See

id. at 579.
Kirchanski, supra note 12, at 578.
Braid, supra note 13.
id.
McNeil, supra note 8.
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necessary infrastructure and skilled workers as evidenced by this
multi-billion dollar domestic industry.

Second, South Africa's problems with providing adequate
medical care may have little to do with the royalties from patent
protection. Mirryena Deeb, of the Pharmaceutical Manufacturing
Association of South Africa, explained that the government of
South Africa was already receiving the lowest prices on drugs, but
public hospitals were sacrificing up to fifty percent of the drugs to
theft. 14 Not only are drugs being stolen and resold in the private
sector, but so are "bed[s], catering equipment, medical equipment,
and computers," all of which drive up the cost of medical services."'
Moreover, the long-standing cartel of middlemen in South Africa
mark up the price of drugs up to 82 percent,"6 compared to the
United .117
States where distributors normally mark up prices only 25
percent.

Lastly, while patent piracy may provide South Africa with
cheaper copies of some drugs, it is difficult to copy new drugs

because to do so often requires new technology.1 I

Perhaps the

greatest threat facing South Africa is that manufacturers, who incur
approximately $359 million in research and development per drug,
may refuse to sell their drugs in a country where there is no patent
protection." 9 Similarly, some drug makers have refused to sell drugs20
in India because of the lack of patent rights for pharmaceuticals.1
One drug that becomes toxic soon after opening has been sold on

the streets of India in jars. 21' Mirryena Deeb stated that "[i]f [drug
manufacturers] can't control how it's made and sold, they won't
22

sell... [because] [t]hey can't afford the liability [from] lawsuits.'
Ultimately, it appears that South Africa can benefit from a

114. See Dlamini, supranote 75.
115. See Benetton, supra note 2.
116. See Braid, supranote 13.
117. See McNeil, supranote 8.
118. See Kirchanski, supranote 12, at 580.
119. See James Love, HAI Seminar: World Trade Organization/GATT,
Pharmaceutical Policies and Essential Drugs (visited Oct. 4, 1998),
<http://www.cptech.org/pharm/bielefeld.htmil>. It must be noted that issue has been
taken with the U.S. Office of Technology Assessment (OTA) estimate of $359
million for the cost of developing a new drug. Id. Mr. Love points out that most of
the $359 estimate is based on "heroic estimates of the costs of pre-clinical research,
much of which is paid for by the government [of the United States], and conducted
in [U.S.] government and university laboratories." Id.
120. See McNeil, supranote 8.
121. See id.
122. See id.
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pharmaceutical patent system and could stand to suffer greatly
without one. The policies against the implementation of a patent
system do not appear applicable to South Africa. There is adequate
infrastructure to support the multi-billion dollar domestic industry,
and the high cost of medicines may have more to do with the
inefficient distribution system than patent royalties.
Indeed,
whether or not the citizens or government of South Africa can
afford the expensive new drugs is irrelevant if drug manufacturers
refuse to introduce new drugs due to a lack of patent protection.
B. The Health Minister'sPower to Authorize ParallelImports.
While nearly all countries have some system of patent
protection, many have taken different positions on the exhaustion of
patents.'23 Many countries have not allowed patent rights to restrict
parallel imports of patented goods.14 In fact, some nations use their
antitrust laws to encourage parallel imports. Richard Sako noted,
in regard to an order issued by Japan's antitrust enforcement agency
to encourage parallel imports, that parallel imports are "generally
considered to promote price competition in a market, and therefore
restrictions on parallel importing are viewed with scrutiny under the
antitrust rules and regulations of most countries."'' 26 Accordingly,
the European Court of Justice has repeatedly stated that "patent
rights do21 7not, in general, provide a basis for stopping parallel
imports.'

Other countries have decided differently. In Boesch v. Graff,
the United States Supreme Court held that "one residing in the
United States could not import or sell articles patented in the United
States without the license or consent of the United States patentee,
even though the articles were patented in a foreign country and
128
purchased from a person authorized to sell them in that country."'
Also, Kenya, which had experimented with allowing parallel
imports, recently banned them citing an abundance of unsafe and

123.
124.
125.

See Love, supra note 55.
See id.
See id.

126.

See id.

127.

See id.

128. See Kremen, supra note 46. It must be noted, however, that the United
States Supreme Court held that the "first sale doctrine, under which [the] owner of
particular copy[righted material] is entitled, with authority of copyright owner, to
sell or otherwise dispose of possession of that copy, is applicable to imported
copies." Quality King Distrib. Inc., v. L'Anza Research Int'l, Inc., 118 S.Ct. 1125
(1998). Thus, parallel imports are permitted under current U.S. copyright law.
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counterfeit drugs.1

1. Potential harmful consequences for South Africa from
sanctioning parallel imports.-The biggest problems in Kenya

"were ascertaining whether parallel imports had been produced in
accordance with good manufacturing practice, and [the
manufacturer's] inability to recall unsafe products." 30 Kenya also
discovered substantial evidence of "substandard and counterfeit
products."''
While the Medicines and Related Substances
Amendment Act stipulates that parallel imports of drugs must
"meet the same quality standards" as the domestically registered
drug, 32 it remains to be seen whether South Africa can ensure the
safety of the drugs.
One of the major reasons why the United States does not
permit parallel imports is the extra burden placed on the FDA to
protect the public from unsafe counterfeits drugs.'33 Critics point out

that "South Africa's border guards are unable to stanch the flow of
illegal immigrants, cocaine, endangered species and even rustled
cattle," and that they would be even less effective against
"counterfeit drugs that have expired and were supposed to be
34
destroyed but were just repackaged.',
Other than these practical concerns, there are also the
underlying fundamental principles of intellectual property
protection to take into consideration. As the United States Supreme
Court explained in Boesch v. Graff, "[t]he franchise which the patent
grants consists altogether in the right to exclude everyone from
making, using, or vending the thing patented without the permission
of the patentee.""'3

The court reasoned that "when [the patent

owner] sells the exclusive privilege of making or vending [his goods]
for use in a particular place, the purchaser buys a portion of the
franchise which the patent confers."' 36 In short, the purchaser of a

patented product shares in the monopoly which "is derived from,
and exercised under, the protection of the United States... [that]
necessarily terminates at the time limited for its continuance by the
129.

See Claire Bisseker, Beware of Counterfeit Medicine, Kenya Warns SA, FIN.

MAIL, Oct. 24, 1997.

130. See id.
131. See id.
132. See Medicines and Related Substances Control Amendment Act, No. 101
(1997) (S. Afr.) § 15(C)(b).
133. See Bisseker, supra note 129.
134. See McNeil, supra note 8.
135. See Boesch v. Graff, 133 U.S. 697, 703 (1890).
136. See id.
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law which created it."' 37 Thus, the right of a purchaser to sell his or

her goods in another country is dependent upon the amount of
monopolistic protection given to the patent holder. As a result, the
question for courts becomes whether the monopoly protection

granted includes being shielded from competition from imports of
the patent owner's products that were originally sold in another
country.
Indeed, parallel imports compel competition between products
where the workings of the free market have been expressly removed
by the grant of patent protection. And while the issue for courts is
whether the law includes protection against parallel imports, the
issue for law-makers should be whether the public is best served by
limiting the monopoly power granted under patent protection by
allowing parallel imports. There are benefits that could be realized
by permitting parallel imports and reducing the amount of
monopoly power granted. The potential harms discussed above
must be weighed against these potential benefits.'
2. Potential benefits for South Africa from allowing parallel
imports.-Some European countries and Japan have decided that it
was in their best interest to allow parallel imports. 3 9 On July 1,
1997, the Supreme Court of Japan declared that allowing parallel
imports did not violate domestic or international law. 40 In the BBS
Aluminum Wheel Case, the petitioner, BBS, sought to prohibit
parallel imports of its products based on a patent entitled "Wheel
for Automobile."'' 4' The products were manufactured, patented, and
sold by BBS in Germany.14 Jap-Auto, the respondent, then bought
the BBS aluminum wheels
in Germany and imported them into
4
Japan and sold them.1 1
In addressing whether or not the importation of BBS goods into
Japan violated international law, the court looked to Article 4b of
the Paris Convention for the Protection of Industrial Property.'"
Article 4b provides that "[platents applied for in the various
137. See id.
138. See Love, supra note 55.
139. See id.
140. See Jinzo Fujino, ParallelImports of Patented Goods. The Supreme Court
Talks About Its Legality (visited Oct. 14, 1998) <http://okuyama.com/c3v01ok.htm>.
141. See id.
142. See id.
143. See id.
144. See id. The Supreme Court of Japan did not discuss the GATT TRIPS
agreement in determining whether parallel imports violate international law. For a
discussion of the TRIPS agreement and parallel imports see discussion supra Parts
III.B.
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countries of the Union by nationals of countries of the Union shall
be independent of patents obtained for the same invention in other
countries whether members of the Union or not.' ' 45 The court then
reasoned that because patent rights in different countries are
of parallel imports is simply
independent of one another, the legality
146
law.
patent
domestic
by
governed
The court began its interpretation of Japan's patent law by
stating that "[t]he protection of an invention under patent law has to
be achieved in harmony with public interest.' ' 147 The court sought to
balance the rights of the patent holder with the interests of the
public. 148 In doing so, the court first noted that a buyer of a product
expects to receive all of the rights that the seller has in that product,
including the right to resell the product. 149 The court then concluded
that requiring the purchaser of goods to receive permission before
reselling them would impede "the free flow of products on the
market," and on account of the enormous amount and importance
of international trade, the freedom to import should not be so
circumscribed." 0 Otherwise, the court stated it "would be contrary
to the purpose of the patent law which aims at encouraging
5
inventions so as to contribute to the development of industry."' '1
Second, the Supreme Court of Japan recognized that a patent
owner receives remuneration when he or she sells the patented
products. 52 And even if parallel imports are allowed, this reward is
still provided for the first disposition of the goods.'5' As a result, the
court concluded that after the first disposition of the patented goods
it is unnecessary to secure the patent holder "double profits through
the process of distribution.' ' 154 Consequently, the court concluded
that patent rights "should no longer extend to the acts of use,
assignment or lease of the product," and that parallel imports were
legal.
145. See Fujino, supra note 140.
146. See id.
147. See id.
148. See id.
149. See id.
150. See Fujino, supra note 140.
151. See id.
152. See id.
153. See id.
154. See id.
155. See Fujino, supra note 140. The court also recognized an exception to patent
rights exhaustion. Id. The court noted that if the parties contract so as to limit the
places the product may be sold to outside of Japan and provide notice to subsequent
purchasers which is "clearly indicated on the product," then the first sale doctrine
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The decision of the Supreme Court of Japan seems to suggest
that the best way "to maintain a balance between the interests of the
patentee and that of the public" is to limit the monopoly granted to
patent holders and allow parallel imports. 156 According to the court,
this would permit the free flow of goods while still retaining the
patent holder's benefits from their monopoly over the first sale of
their goods.
3. Weighing the benefits and costs of parallelimports.-Just as
in Japan, the proper balance between the interests of the patent
holders and the public in South Africa would seem to be to restrict
the monopoly granted by patents. Doing so would promote more
imports and make available desperately needed lower prices
through the resulting competition. Indeed, the importance of such
competition is magnified in poorer countries, such as South Africa,
where consumers do not enjoy the strong competition found in more
developed economies such as the United States or Japan."' Some
medicines, such as the medicine for malaria, are indeed priced
higher in South Africa than in Europe and the United States. 159
Furthermore, if Mirryena Deeb, of the Pharmaceutical
Manufacturing Association of South Africa is correct that South6
Africa already has access to some of the lowest prices on drugs,' 0
then the pharmaceutical manufacturers have nothing to fear. If
prices are not lower in other countries, then there would be no
reason for the Minister of Health to import them into South Africa.
And even if the Minister of Health was to import drugs from other
countries, the manufacturer still obtains the royalty upon the first
sale of the medicine in the foreign country. Hence, just as the
highest court of Japan reasoned, there is no reason to provide
companies "double-profits" through the chains of distribution. 161 In

does not apply. Id. The court reasoned that subsequent purchasers will then be able
to "decide whether or not to buy the patented product, taking into account the
presence of such restrictions." Id. However, it would seem to be quite easy for a
patent holder to have its sales contracts include language exempting parallel
imports. Id. The patent holder has a monopoly over his or her patented goods and
therefore has a great deal of leverage over the buyer in negotiations. Fujino, supra
note 140. As a result, the court's decision may serve to prohibit parallel imports,
which is obviously counter to the policies explained by the court and those espoused
in this comment.
156. See id.
157. See id.
158. See Love, supra note 55.
159. See id.
160. See Dlamini, supra note 75.
161. See Fujino, supra note 140.
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short, companies still receive the benefit of patent protection, but
are less capable to charge higher prices in countries that lack strong
domestic competition.
Also, parallel imports may drastically lower the prices of drugs.
Comments from the Consumer Project on Technology pointed out
that in the United Kingdom HIV drug S162
prices were on average 30
percent cheaper from parallel importers.
Parallel imports
therefore could result in a tremendous amount of savings for South
Africa, where AIDS medicines can cost a single patient up to $1,000
per month. 16 Dr. Zuma stated that the new Act is projected to save
up to ten percent on the total amount spent on pharmaceuticals.
This could provide a dramatic increase in the availability of medical
care for people in South Africa, which is second only to Portugal in
the percentage
of gross domestic product spent on pharma16 1
ceuticals.
Lastly, the risk of unsafe products does not seem sufficient
enough to warrant prohibiting parallel imports. Patients in South
Africa are probably more fearful of not having any medical
attention than receiving imposter drugs. One-forth of the rural
clinics in South Africa do not have running water or electricity, and
long lines of patients are often unable to receive any medical
attention at all because of a lack of supplies and medical staff.166 In
addition, under the new law, not all medicines will be allowed to be
imported. The Minister of Health determines which drugs are
allowed to be imported, who may do the importing, and under what
conditions the drugs may be imported.16 This being so, there should
not be any more illegal drugs in South African markets than there
currently are because patent knock-offs or unauthorized parallel
imports are both still illegal. In fact, there is more of an incentive to
import unsafe imposter drugs when parallel imports are not allowed
because it is more profitable if the prices of patented drugs are kept
higher. In the end, and despite the fear of unsafe products, it does
appear wise for South Africa to promote competition by increasing
the free market incentives to benefit many of its poor citizens by
limiting the monopoly granted by patents.

162. See Love, supra note 55.
163. See McNeil, supra note 8.
164. See Bisseker, supra note 129.
165. See McNeil, supra note 8.
166. See Benetton, supra note 2.
167. See Medicines and Related Substances Control Amendment Act, No. 101
(1997) (S. Afr.) § 15(C)(b).

1999] SouTH

AFRICA: MEDICINES AND RELATED SUBSTANCE LAW

197

VI. Conclusion
In light of the infirmity suffered by so many South Africans and
their inability to obtain even the most basic health care, South
Africa diverged from traditional notions of intellectual property
rights. There is little doubt that the Medicines and Related
Substances Control Amendment Act lessened the level of
intellectual property protection formerly provided for pharmaceuticals in South Africa. It is less clear to what extent protection
has been diminished.
Section 15(C) has been surrounded by international
controversy for over a year, and despite the repeated urging by
pharmaceutical companies and the United States to amend the
language and clarify the law's intention, the law was nonetheless
passed by the legislature and signed into law by President Nelson
Mandela. 1 9 While it seems very unlikely that the hazy language of
the act was intended to end patent rights for pharmaceuticals, the
fear on behalf of the pharmaceutical companies and United States is
justified. As discussed, the new law has potentially serious
ramifications for South African citizens and pharmaceutical
companies.
If the new law is intended to effectively dissolve patent rights
for pharmaceuticals, then South Africa has violated its obligations
under the TRIPS agreement. Even so, the greatest danger South
Africa would face is being denied access to new advances in
medicine. Pharmaceutical manufacturers have threatened that if the
law does end patent rights for pharmaceuticals, then they will refuse
to introduce any new drugs, including Aids vaccines.170 A number of
companies have already put investment plans on hold, pending
clarification of the new law. 7' Indeed, companies have suggested
they are willing to let People die unless patent protection is provided
for pharmaceuticals.
Fortunately, the law does not appear to end patent protection,
but merely permits the Minister of Health to authorize parallel
imports. In this case, the new law would not violate international
law because it meets the minimum level of protection consistent with
South Africa's TRIPS obligations. The new law does not allow
patented drugs to be copied, but only allows patented drugs to be
168.
169.
170.
171.
172.
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See id.
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imported, on terms and conditions specified by the Minister of
Health, from other countries where the pharmaceutical companies
sell them cheaper. Multinational companies will still receive their
royalties from the first sale of the medicine, but will be less able to
charge higher prices in countries that lack developed and
competitive markets. As a result, there should be more conformity
in international drug prices and lower prices in South Africa.
Parallel imports provide a limitation on the monopoly granted
through patent protection. There is no such thing as absolute patent
protection. Even in countries that provide high levels of patent
protection, such as the United States, there are limits placed on
patents, such as types and durations. For South Africa, allowing
parallel imports seems to strike the correct balance between
providing pharmaceutical companies exclusivity for their inventions
and providing the public desperately needed medical care.
David Benjamin Snyder

